Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity

Daniel S. Leventhal (), Anna Sokolovska (), Ning Li, Christopher Plescia, Starsha A. Kolodziej, Carey W. Gallant, Rudy Christmas, Jian-Rong Gao, Michael J. James, Andres Abin-Fuentes, Munira Momin, Christopher Bergeron, Adam Fisher, Paul F. Miller, Kip A. West and Jose M. Lora ()
Additional contact information
Daniel S. Leventhal: Synlogic, Inc.
Anna Sokolovska: Synlogic, Inc.
Ning Li: Synlogic, Inc.
Christopher Plescia: Synlogic, Inc.
Starsha A. Kolodziej: Synlogic, Inc.
Carey W. Gallant: Synlogic, Inc.
Rudy Christmas: Synlogic, Inc.
Jian-Rong Gao: Synlogic, Inc.
Michael J. James: Synlogic, Inc.
Andres Abin-Fuentes: Synlogic, Inc.
Munira Momin: Synlogic, Inc.
Christopher Bergeron: Synlogic, Inc.
Adam Fisher: Synlogic, Inc.
Paul F. Miller: Synlogic, Inc.
Kip A. West: Synlogic, Inc.
Jose M. Lora: Synlogic, Inc.

Nature Communications, 2020, vol. 11, issue 1, 1-15

Abstract: Abstract Synthetic biology is a powerful tool to create therapeutics which can be rationally designed to enable unique and combinatorial functionalities. Here we utilize non-pathogenic E coli Nissle as a versatile platform for the development of a living biotherapeutic for the treatment of cancer. The engineered bacterial strain, referred to as SYNB1891, targets STING-activation to phagocytic antigen-presenting cells (APCs) in the tumor and activates complementary innate immune pathways. SYNB1891 treatment results in efficacious antitumor immunity with the formation of immunological memory in murine tumor models and robust activation of human APCs. SYNB1891 is designed to meet manufacturability and regulatory requirements with built in biocontainment features which do not compromise its efficacy. This work provides a roadmap for the development of future therapeutics and demonstrates the transformative potential of synthetic biology for the treatment of human disease when drug development criteria are incorporated into the design process for a living medicine.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-16602-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-16602-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-16602-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().